Taiga Nishihori, MD: Is Maintenance Ixazomab Feasible in High-Risk Myeloma?

Posted: Friday, June 4, 2021

Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, talks about why a study of maintenance ixazomab after transplant in patients with high-risk myeloma had to be suspended, and the lessons learned in preventing or reducing toxicities in this setting.